Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX)

Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats.

On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 2026 and said it is updating its financial model to align with the new structure. Piper added that its estimates still include the Life Sciences segment, even though that unit is set to transition to Waters in the coming weeks.

Earlier in the month, BD announced plans to invest $110 million to expand production of prefillable syringes, a move aimed at supporting faster delivery of biologic and GLP-1 drugs while strengthening pharmaceutical manufacturing in the U.S. The investment brings BD Neopak™ Glass Prefillable Syringe production to Columbus, Nebraska, and is expected to create about 120 new jobs while improving supply resilience within the company’s Pharmaceutical Systems business.

Of the total investment, $100 million will go toward establishing Neopak™ syringe production at the Columbus facility, with initial supply targeted for mid-2026. The company will also use the funds to upgrade existing lines and expand capacity across the site to keep up with rising global demand for advanced injectable products. An additional $10 million will be directed toward enhancing cannula manufacturing, and together these projects are expected to support roughly 120 new roles.

Becton, Dickinson and Company (NYSE:BDX) remains one of the world’s largest medical technology companies, with a broad focus on advancing healthcare through improvements in medical discovery, diagnostics, and the delivery of care.

While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Companies that Just Started Paying Dividends and 10 Best Monthly Dividend Stocks to Buy Now

Disclosure: None.